Most health discussions about tobacco focus on combustion byproducts like tar and carbon monoxide, but a comprehensive mechanistic review reframes nicotine itself as a primary cardiovascular toxicant — a distinction with major implications for vapers, patch users, and anyone relying on nicotine replacement therapy as a 'safe' alternative.
The review, published in Biomedicine & Pharmacotherapy, maps six interconnected molecular pathways through which nicotine destabilizes cardiovascular function independent of tobacco smoke. Nicotine activates NADPH oxidase and impairs mitochondrial electron transport, generating reactive oxygen species that deplete nitric oxide — the endothelium's primary vasodilatory signal. Simultaneously, it upregulates acid sphingomyelinase, driving ceramide accumulation in lipid rafts that triggers NLRP3 inflammasome activation and systemic vascular inflammation. Through augmented sympathetic nervous system tone, nicotine chronically elevates heart rate and arterial pressure, promoting structural cardiac remodeling toward hypertrophy and fibrosis. The metabolic sequelae are equally concerning: nicotine disrupts insulin signaling via redox-sensitive pathways, induces podocyte injury in renal glomeruli, and accelerates chronic kidney disease progression — creating a cardiorenal risk amplification loop.
This synthesis matters beyond its mechanistic thoroughness. The ceramide-NLRP3 axis is a relatively underappreciated nicotine-specific pathway that links lipid metabolism disruption to innate immune activation, potentially explaining why nicotine users show elevated cardiovascular risk even without conventional combustion exposure. Therapeutically, the review flags inhibitors of ceramide signaling and inflammasome pathways as emerging targets, which aligns with broader cardiometabolic drug development trends but remains largely preclinical. A central limitation is that most underlying mechanistic evidence derives from animal models and in-vitro systems; human pharmacodynamic confirmation at doses matching real-world nicotine product use is sparse. As e-cigarette and nicotine pouch consumption rises globally, this mechanistic clarification is incrementally important — though it will require translational clinical trials before reshaping public health guidance.